Ates, G.Ozekinci, T.Yildiz, T.Danis, R.2024-04-242024-04-2420091310-28181314-3530https://doi.org/10.1080/13102818.2009.10817646https://hdl.handle.net/11468/16941Early diagnosis and proper treatment of latent tuberculosis infection (LTB1) in patients with end stage renal diseases (ESRD) is critical to reduce increased reactivation risk of LTB1. However; this condition is known to decrease responsiveness to the tubercidin skin test (TST). A new, diagnostic test [QuantiFERON-TB Gold in-tube (QFT-GIT)] has been developed using mycobacterium tuberculosis specific antigens for the identification of LTB1. We aimed to evaluate the two test methods among hemodialysis patients for their diagnostic usefulness. We performed a cross-sectional comparison study on 275 ESRD recruits tested for LTB1 using the TST and QTF-GIT. Valid TST and QFT-GIT results were available for 259 and 246 patients, respectively. Overall, 46.7% of 246 patients were tested positive for the QTF-GIT and 35.5% of 259 were found to be TST positive. The QTF-GIT but not TST results were correlated with the history of tuberculosis: conversely, QTF-GIT and TST results were not associated with contact to tuberculosis. Moreover, QTF-GIT test generated indeterminate results in 10.4% of subjects. The concurrence between the two test methods was poor (67.8%, kappa = 0.34). Inconsistent results, most of which were, tested as TST negative/QTF-GIT positive were observed in 32.2% patients. The present results suggest that the QTF-GIT is more sensitive than TST in the detection of LTB1 among renal dialysis patients. Nevertheless, large longitudinal studies are required for more accurate results.eninfo:eu-repo/semantics/openAccessLatent TuberculosisTuberculosisInterferon GammaDialysisRenal FailureArticle23212421246WOS:0002663753000162-s2.0-7644911486310.1080/13102818.2009.10817646Q3Q4